Clinical TrialJul 17, 2026, 10:26 AM
Immatics to Present PRAME Clinical Data at ESMO Congress 2026
AI Summary
Immatics N.V. announced it will present three clinical data updates at the European Society for Medical Oncology (ESMO) Congress 2026. The presentations will include Phase 1b data for anzu-cel in metastatic cutaneous and uveal melanoma, Phase 1 data for IMA203CD8 across various PRAME-positive solid tumors, and Phase 1b data for IMA402 at its recommended Phase 2 dose range. These updates underscore the broad applicability and continued development of Immatics' PRAME franchise across cell therapies and bispecifics.
Key Highlights
- Immatics to present three clinical data updates at ESMO Congress 2026.
- Phase 1b data for anzu-cel in metastatic cutaneous and uveal melanoma.
- Phase 1 data for IMA203CD8 across multiple PRAME-positive solid tumors.
- Phase 1b data for IMA402 at recommended Phase 2 dose (RP2D) range.
- Presentations highlight breadth of PRAME franchise across two therapeutic modalities.
- ESMO Congress 2026 to be held from October 23-27, 2026, in Madrid, Spain.
- Full abstracts will be published on the ESMO website on October 19, 2026.
Price Impact
More from IMTX